RxDoctor Payments Data

Ileana Green

Family · Gary, INNPI 1477042505

Payments from drug & device makers

$5,010in general payments, 2019–2025

Across 175 payments — averaging $28.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$648
  • Inspire Medical Systems, Inc.$464
  • E.r. Squibb & Sons, L.L.C.$309
  • Novartis$308
  • Biohaven Pharmaceutical Holding Company Ltd.$269
  • AstraZeneca$239
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$4,990100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,010 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$26,866
Medicare patients
143
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$31,402
JardianceEmpagliflozin20$27,691
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$22,154
RexultiBrexpiprazole15$17,469
LinzessLinaclotide18$16,642
MounjaroTirzepatide11$10,984
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl77$6,661
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,466
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen140$2,249
Celecoxib22$1,724
Albuterol Sulfate HfaAlbuterol Sulfate68$1,631
Diclofenac Sodium32$1,349
Quetiapine Fumarate25$1,254
Roflumilast12$980
Gabapentin79$867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$31,40219 claims
GSKTrelegy Ellipta$19$22,15432 claims
Otsuka America Pharmaceutical, Inc.Rexulti$47$17,46915 claims
AbbVieLinzess$224$16,64218 claims
Lilly USA, LLCMounjaro$146$10,98411 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$75$31320 claims
Almatica Pharma LLCSertraline Hcl$29$30323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.

Other family in Gary

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →